A61K 38/2026
Il-4
Official title: {il-4}
A61K38/2026 (Il-4) appears on 216 US grants and 408 published applications in this corpus.
Search patents in A61K- Granted patents
- 216
- Published applications
- 408
- Assignees
- 215
- Inventors
- 643
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 5 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 3 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 4 |
| 2002 | 3 | 6 |
| 2003 | 2 | 11 |
| 2004 | 2 | 20 |
| 2005 | 4 | 11 |
| 2006 | 3 | 10 |
| 2007 | 7 | 20 |
| 2008 | 5 | 10 |
| 2009 | 2 | 17 |
| 2010 | 2 | 22 |
| 2011 | 6 | 23 |
| 2012 | 6 | 12 |
| 2013 | 6 | 15 |
| 2014 | 9 | 18 |
| 2015 | 16 | 24 |
| 2016 | 8 | 20 |
| 2017 | 9 | 13 |
| 2018 | 13 | 7 |
| 2019 | 6 | 29 |
| 2020 | 19 | 18 |
| 2021 | 9 | 14 |
| 2022 | 18 | 29 |
| 2023 | 6 | 12 |
| 2024 | 6 | 15 |
| 2025 | 14 | 16 |
| 2026 | 4 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)11 Aug 2026US 12,702,710 B2Medicenna Therapeutics Inc.
- System and method for the production, formulation and use of conditioned media, cultured cells and the factors included therein10 Mar 2026US 12,569,537 B2Rinati Skin, LLC
- Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof17 Feb 2026US 12,552,849 B2Deka Biosciences, Inc.
- Stem cell-derived exosomes containing pain regulators, and uses thereof27 Jan 2026US 12,533,317 B2Exostemtech Co., Ltd.
- Interleukin-4 receptor-binding fusion proteins and uses thereof23 Dec 2025US 12,503,496 B2Medicenna Therapeutics Inc.
- Targeted lipid nanoparticles for treating central nervous system injuries8 Oct 2026US 2026/0306665 A1Wisconsin Alumni Research Foundation
- Synthekine Compositions and Methods of Use10 Sep 2026US 2026/0263562 A1The Board of Trustees of the Leland Stanford Junior University
- Method and composition for preventing or treating myopia20 Aug 2026US 2026/0240925 A1Tsubota Laboratory, Inc.
- Use of immunomodulation methods in combination with cytokine fusions for disease treatment13 Aug 2026US 2026/0232820 A1Medicenna Therapeutics Inc.
- Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof6 Aug 2026US 2026/0226123 A1Deka Biosciences, Inc.
Most cited
By later US patents
- Stabilization of protein formulations113US 5,358,708 ASchering Corporation · 1994
- Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody83US 7,682,612 B1Biogen Idec Inc. · 2010
- Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase75US 6,905,669 B2SuperGen, Inc. · 2005
- B7-H1 and methods of diagnosis, prognosis, and treatment of cancer68US 7,892,540 B2Mayo Foundation for Medical Education and Research · 2011
- Compositions and methods for systemic inhibition of cartilage degradation67US 7,067,144 B2Omeros Corporation · 2006